Quarterly report pursuant to Section 13 or 15(d)

Consolidated Statements of Cash Flows (Unaudited)

v3.4.0.3
Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2016
Mar. 31, 2015
CASH FLOWS FROM OPERATING ACTIVITIES    
Net (loss) $ (5,254) $ (4,278)
Adjustments to reconcile net (loss) to net cash (used in) operating activities:    
Depreciation 518 348
Amortization 87 9
Provision for bad debts 0 221
Stock-based compensation 534 696
Change in fair value of business acquisition (34) 90
Change in fair value of warrant liability (17) 15
Amortization of debt issuance costs 4 0
Loss in equity method investment 12 207
Changes in:    
Accounts receivable (1,828) (17)
Other current assets 295 23
Other non-current assets 3 0
Accounts payable, accrued expenses and deferred revenue (101) (239)
Deferred rent and other (6) (18)
Net cash (used in) operating activities (5,787) (3,105)
CASH FLOWS FROM INVESTING ACTIVITIES    
Purchase of fixed assets (319) (83)
Patent costs (39) (40)
Net cash (used in) investing activities (358) (123)
CASH FLOWS FROM FINANCING ACTIVITIES    
Principal payments on capital lease obligations (41) (14)
Net cash (used in) financing activities (41) (14)
Net (decrease) in cash and cash equivalents (6,186) (3,242)
CASH AND CASH EQUIVALENTS    
Beginning 19,459 25,554
Ending 13,273 22,312
SUPPLEMENTAL CASH FLOW DISCLOSURE    
Cash paid for interest 97 34
BioServe    
Adjustments to reconcile net (loss) to net cash (used in) operating activities:    
Change in fair value of business acquisition (34) 90
Gentris [Member]    
Adjustments to reconcile net (loss) to net cash (used in) operating activities:    
Change in fair value of business acquisition $ 0 $ (162)